1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, L.; Wei, Y.; Wacheck, V.; Heymach, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Predicting fitness for chemotherapy in older adults with metastatic bladder cancer
    Meeting Abstract

    Russell, B.; Fein, D. E. C.; Berg, S. A.; Gupta, S.; Rosenberg, J. E.; Choueiri, T. K.; Bellmunt, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma
    Meeting Abstract

    Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Shaverdian, N.; Ricciuti, B.; Alessi, J. V. M.; De Giglio, A.; Pecci, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy (SLL) when administered in combination with bevacizumab (BEV) and neoadjuvant chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian cancer (EOC)
    Meeting Abstract

    Jazaeri, A. A.; Grisham, R. N.; Gaillard, S.; How, J. A.; Hazard, S.; Musso, L.; Kyi, C.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab
    Meeting Abstract

    Kyi, C.; Van Dongen, M.; Rottey, S.; Bermejo, I. M.; Mittag, D.; Gouveia, D.; Bol, K.; Yan, C.; Joe, A. K.; Laus, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US
    Meeting Abstract

    Razavi, P.; Ahmed, M.; Roush, A.; Parikh, R.; Hitchens, A.; Shen, S.; Safonov, A.; Jhaveri, K. L.; Robson, M. E.; Peacock, N. W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma
    Meeting Abstract

    Avutu, V.; Livingston, J. A.; Federman, N.; Cranmer, L. D.; Gaspar, N.; Toulmonde, M.; Pressey, J. G.; Brahmi, M.; Poklepovic, A. S.; Shi, Q.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment
    Meeting Abstract

    Postow, M. A.; Burgos, G.; DeCongelio, M.; Palaia, J.; Ejzykowicz, F.; Patel, D.; Rosenblatt, L.; Modi, K.; Pittman, Z.; Honomichl, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Immune-related adverse event prediction and influential factor identification
    Meeting Abstract

    Zhang, Y.; Lev-Ari, S.; Shah, N. J.; Gupta, S.; Zaemes, J. P.; Alaoui, A.; McGarvey, P.; Atkins, M. B.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769)
    Meeting Abstract

    Traina, T. A.; Chen, Y.; Khoury, K.; Rugo, H. S.; Mayer, E. L.; Carey, L. A.; Melisko, M. E.; Syldor, A.; Friedman, C.; Savoie, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save